Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate

Drug Metabolism and Disposition

Volumn 26, Issue 7, 1998, Pages 609-616

  Lillibridge, James H ^b   Liang, Bai Hong ^b   Kerr, Bradley M ^b   Webber, Stephanie ^b   Quart, Barry ^b   Shetty, Bhasker V ^b   Lee, Caroline A ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; INDINAVIR; KETOCONAZOLE; NELFINAVIR; PACLITAXEL; PHENACETIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; DEMETHYLATION; DRUG COMPETITION; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER MICROSOME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HIV PROTEASE INHIBITORS; HUMANS; ISOENZYMES; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NELFINAVIR;

EID: 0344765487     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Abbott Laboratories (February, 1996) Prescribing information for NORVIR (ritonavir) capsules. North Chicago, IL.
2. Agouron Pharmaceuticals Inc. (March, 1997) Prescribing information for VIRACEPT (nelfinavir mesylate) tablets and oral powder. La Jolla, CA.
3. Amacher DE, Schomaker SJ and Retsema JA (1991) Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 35:1186-1190.
4. Cato A, Cavanaugh JH, Shi H, Hsu A, Granneman GR and Leonard J (1996) Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin (Abstract). Abstracts of the 11th International Conference on AIDS, Vancouver.
5. Chiba M, Hensleigh M, Nishime JA, Balani SK and Lin JH (1996) Role of cytochrome P450 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:307-314.
6. Chiba M, Nishime JA and Lin JH (1995) Potent and selective inactivation of human liver microsomal cytochrome P450 isoform by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275:1527-1534.
7. Clinical update: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. (1996) Morb Mortal Wkly Rep 45:921-925.
8. Eagling VA, Back DJ and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by three protease inhibitors: Ritonavir, saquinavir, and indinavir (Abstract). 6th European ISSX Meeting, Gothenburg, Sweden. P. 177.
9. Eller MG and Okerholm RA (1991) Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther 49:120.
10. Estabrook RW, Peterson J, Baron J and Hildebrandt A (1972) The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism. Methods Pharmacol 2:303-350.
11. Fauci AS, Bartlett JG, Goosby EP and Smith MD (1997) Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation (Federal Register-draft document).
12. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
13. Gibaldi M (1996) Progress in the treatment of HIV infection. Pharm New 3:27-32.
14. Guengerich FP, Kim DH and Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
15. Guengerich FP, Muller-Enoch D and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
16. Hall SD, Guengerich FP, Branch RA and Wilkinson GR (1987) Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther 240:216-222.
17. Harb GE, Alldredge BK, Coleman R and Jacobson MA (1993) Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquired Immune Defic Syndr 6:919-926.
18. Hoechst Marion Roussel, Inc. (July, 1996) Prescribing information for ALLEGRA (fexofenadine hydrochloride) capsules. Kansas City, MO.
19. Honig PK, Woosley RL, Zamani K, Conner DP and Cantilena LR (1992) Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238.
20. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518.
21. Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N and Koudriakova T (1997) Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 61:554-562.
22. Indinavir (MK 639) Pharmacokinetic Study Group (1996) Indinavir (MK 639): Drug interaction studies (Abstract). Abstracts of the 11th International Conference on AIDS, Vancouver.
23. Jefcoate CR (1978) Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol 52:258-279.
24. Joceyln PC (1972) Biochemistry of the SH Group, p 63-93, Academic Press, London.
25. Joellenbeck Z, Qian L, Zarba A and Groopman JD (1992) Urinary 6 beta-hydroxycortisol/ cortisol ratios measured by high-performance liquid chromatography for use as a biomarker for the human cytochrome P-450 3A4. Cancer Epidemiol Biomarkers Prev 1:567-572.
26. Jurima-Romet M, Crawford K, Cyr T and Inaba T (1994) Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
27. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW and Leonard JM (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654-660.
28. Kerr B, Yuen G, Daniels R, Quart B, Kravcik S, Sahai J and Anderson R (1997) Strategic approach to nelfinavir mesylate drug interactions involving CYP3A metabolism (Abstract). Abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV-infection, Hamburg, Germany.
29. Kravcik S, Sahai J, Kerr B, Anderson R, Buss N, Seguin I, Bristow N, Farnsworth A and Salgo M (1997) Nelfinavir mesylate increases saquinavir-soft gel capsule exposure in HIV+ patients (Abstract). Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC. P. 132.
30. Kumar GN, Oatis JE Jr, Thornburg KR, Heldrich FJ, Hazard ES and Walle T (1994) 6α-Hydroxypaclitaxel: Isolation and identification of the major metabolite of paclitaxel in human liver microsomes. Drug Metab Dispos 22:177-179.
31. Kumar GN, Rodrigues A, Buko AM and Dennison JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
32. McCrea J, Buss N, Stone J, Carides A, Dru J, Stewart F, Brown A, Yeh K, Salgo M, Waldman S and Deutsch P (1997) Indinavir-saquinavir single dose pharmacokinetic study (Abstract). Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC. P. 177.
33. McLean MR, Bauer U, Amaro AR and Robertson LW (1996) Identification of catechol and hydroquinone metabolites of 4-monochlorobiphenyl Chem Res Toxicol 9:159-164.
34. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tijia JF, Gibbons SE, Breckenridge AM and Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
35. Miners JO and Birkett DJ (1996) Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 272:139-145.
36. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes: Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37: 1137-1144.
37. Nagata K, Liberato DJ, Gillete JR and Sasame HA (1986) An unusual metabolite of testosterone 17β-hydroxy-4,6-androstadiene-3-one. Drug Metab Dispos 14:559-565.
38. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
39. Ortiz de Montellano PR (1995) Cytochrome P450: Structure, Mechanism and Biochemistry, 2nd ed, pp. 305-364, Plenum Press, New York.
40. Ortiz de Montellano PR and Matthews JM (1981) Autocatalytic alkylation of the cytochrome P450 prosthetic haem group by 1-aminobenzotriazole. Biochem J 195:761-764.
41. Podoll TD, Kunze KL, Thummel KE and Fisher JM (1996) Mechanism-based inactivation of cytochrome P450 3A4 by midazolam (Abstract). XIth International Symposium on Microsomes and Drug Oxidations, University of California, Los Angeles, CA.
42. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ and Harris JW (1994) Selective biotransformation of taxol to 6a-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
43. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, Li D and Guzelian PS (1993) Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18:1254-1262.
44. Shimada T, Misono KS and Guengerich FP (1986) Human liver microsomal cytochrome P450 mephenytoin 4-hydroxylase, prototype of genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:909-921.
45. Silverman RB (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology. Vol. 1, pp. 3-27, CRC Press, Boca Raton, FL.
46. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
47. Thummel KE, Kharasch ED, Podoll T and Kunze K (1993) Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 21:350-357.
48. Vickery LE (1992) Active-site directed inhibitors of steroid hydroxylase cytochrome P450. Methods Enzymol 206:548-558.
49. Wilkinson JM, Martin-Powers TM, Miller JH and Terry KM (January, 1996) HPLC analysis of terfenadine and terfenadine acid metabolite in human plasma. Project ZIC Validation Report, Pharmaco LSR, Richmond, VA.
50. Wisconsin Analytical and Research Services, Division of Pharmaceutical Product Development-Clinical Research Unit, Inc. (July, 1996) Determination of cortisol and 6β-hydroxycortisol in human urine by high performance liquid chromatography (WARS-P341.01). Validation Study Report No. WARS-4161V. Madison, WI.
51. Wu EY, Sandoval TM, Lee CA, Zhang K, Liang B-H and Shetty BV (1996) In vitro metabolism studies with the HIV-1 protease inhibitor. Viracept (AG1343) (Abstract). 7th North American ISSX Meeting, San Diego. P. 326.
52. Wu EY, Wilkinson JM, Naret DG, Daniels VL, Jefferson-Willams L, Khalil DA and Shetty BV (1997) High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B 695:373-380.
53. Zhang K, Wu E, Patick A, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Ishikawa T, Kogayu M, Talaat R, Wagner C, Shetty B and Webber S (1997) Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: Quantitation by LC-MS/MS and antiviral activities (Abstract). 6th European ISSX Meeting, Gothenburg, Sweden. P. 128.